| 东方证券股份有限公司 | | | --- | --- | | 关于江苏博俊工业科技股份有限公司 | | | 保荐机构名称：东方证券股份有限公司 | 被保荐公司简称：博俊科技 | | 保荐代表人姓名：刘俊清 | 联系电话：021-2315 3434 | | 保荐代表人姓名：陈华明 | 联系电话：021-2315 3684 | | 一、保荐工作概述 | | | 项目 | 工作内容 | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | | | 是 | | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | （1）查询公司募集资金专户次数 | 每月查询一次 | | （2）公司募集资金项目进展是否与信息披露文 | | | 是 | | | 件一致 | | | （1）列席公司股东大会次数 0 | 次，均事前或事后审阅会议议案 | | （2）列席公司董事会次数 ...

东吴证券研报指出，东方证券2025H1归母净利润34.6亿元，同比+64.0%；对应EPS0.40元，ROE4.3%， 同比+1.6pct。第二季度实现归母净利润20.3亿元，同比+65.5%，环比+41.2%。交投活跃度回升背景 下，公司经纪业务收入同比高增；投行业务收入逆市增长，股权及债券承销规模均大幅提升；资管业务 收入同比下滑，东证资管及汇添富AUM仍稳健增长；另外，公司自营业务表现亮眼。该行看好交投活 跃度回升背景下公司在财富管理转型及基金管理方面的增量，维持"买入"评级。 ...

东方证券股份有限公司研究员韩潇锐、蒯剑、薛宏伟9月1日发布研报《蓝思科技：业绩稳健增长下半年 有望加速》称，维持给予蓝思科技买入评级。 中国经济网北京9月2日讯蓝思科技（300433）(300433.SZ)今日收报30.03元，跌幅7.14%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東方證券股份有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600958 | 說明 | 上海證券交易所 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 7,469,482,864 | RMB | | 1 RMB | | 7,469,482,864 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 7,469,482,864 | RMB | | 1 RMB | | 7,469,482,864 | | 2. 股份分類 | 普通股 | 股份類 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東方證券股份有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600958 | 說明 | 上海證券交易所 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 7,469,482,864 | RMB | | 1 RMB | | 7,469,482,864 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 7,469,482,864 | RMB | | 1 RMB | | 7,469,482,864 | | 2. 股份分類 | 普通股 | 股份類 ...

Core Viewpoint - The company Si Er Te (002538.SZ) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to adjustments in its financial statements [1] Financial Performance Summary - In the first half of 2025, the company achieved operating revenue of 2.183 billion yuan, representing a year-on-year increase of 7.15% [2][3] - The net profit attributable to shareholders decreased by 43.60% to 95.18 million yuan compared to the same period last year [2][3] - The net profit after deducting non-recurring gains and losses also fell by 42.47% to 90.11 million yuan [2][3] - The net cash flow from operating activities was 94.35 million yuan, down 62.04% year-on-year [2][3] - Basic and diluted earnings per share both dropped by 45.00% to 0.11 yuan [3] - The weighted average return on net assets decreased to 1.81% from 3.20% in the previous year [3] Asset Summary - As of the end of the reporting period, total assets amounted to 6.326 billion yuan, a decrease of 0.92% from the previous year [3] - The net assets attributable to shareholders were 5.306 billion yuan, down 0.11% from the previous year [3]

Core Viewpoint - Dongfang Securities reported its 2025 interim results, aligning with performance forecasts, showing significant growth in revenue and net profit [1] Group 1: Financial Performance - In 1H25, Dongfang Securities achieved operating revenue of 8 billion, a year-on-year increase of 38.9% [1] - The net profit attributable to shareholders reached 3.46 billion, reflecting a year-on-year growth of 64.0% [1] - The weighted average ROE (unannualized) for 1H25 was 4.27%, up 1.61 percentage points year-on-year [1] Group 2: Investment Business Performance - The company reported a main revenue of 7.94 billion from its securities business, a year-on-year increase of 39.6% [1] - Breakdown of main revenue: brokerage income was 1.37 billion (+31.1%), investment banking income was 720 million (+31.6%), asset management income was 600 million (-15.1%), net interest income was 460 million (-33.4%), and net investment income was 4.25 billion (+85.7%) [1] - In terms of revenue composition, brokerage accounted for 17.3%, investment banking 9.1%, asset management 7.6%, net investment 53.5%, and net interest 5.8% [1] Group 3: Asset and Investment Management - As of the end of 2Q25, total assets were 437.4 billion, up 4.7% from the beginning of the year [2] - Investment assets reached 242.5 billion, an increase of 8.3% year-to-date [2] - The investment leverage ratio was 2.86x, up 0.11x year-to-date, with an investment return rate of 3.65%, an increase of 1.37 percentage points year-on-year [2] Group 4: Wealth Management and Brokerage - The company reported net income from agency buying of 810 million, a year-on-year increase of 23.4% [3] - The number of customer accounts reached 3.139 million, up 7.5% from the beginning of the year, with total custodial assets of 959.3 billion, up 9.2% [3] - The company is transitioning its wealth management business towards a "buy-side advisory" model, enhancing customer scale [3]

Investment Rating - The report maintains an "Overweight" rating for the securities industry [1]. Core Insights - The capital market continues to recover, with a significant increase in net profit for the first half of 2025, up 51% year-on-year, leading to an upward revision of the annual profit forecast [1][8]. - The average daily trading volume of stock funds reached 15,703 billion yuan, a 63% increase year-on-year, indicating a robust market activity [1][13]. - The report highlights the strong performance of major securities firms, recommending companies such as CITIC Securities, China Galaxy, and Huatai Securities due to their competitive advantages in the current market environment [8]. Summary by Sections 1. Market Performance - The securities industry saw a 23% increase in revenue and a 40% increase in net profit in the first half of 2025, with 150 securities firms reporting a total revenue of 2,510 billion yuan [42]. - The average return on equity (ROE) for the first half of 2025 was 3.53%, an increase of 0.85 percentage points year-on-year [42]. - The average daily trading volume for stock funds was 15,703 billion yuan, reflecting a 63% year-on-year growth [13][19]. 2. Brokerage Business - Brokerage income for listed firms increased by 47% year-on-year, totaling 592 billion yuan in the first half of 2025 [2]. - The commission rate decreased from 0.020% in 2024 to 0.019% in the first half of 2025, indicating a competitive pricing environment [2][44]. 3. Investment Banking - Investment banking revenue grew by 18% year-on-year, benefiting from a recovery in refinancing activities [2][29]. - A total of 51 IPOs were issued in the first half of 2025, raising 37.4 billion yuan, which represents a 15% increase in the number of IPOs and a 16% increase in funds raised compared to the previous year [22][29]. 4. Asset Management - Asset management income slightly declined by 3% year-on-year, with a total of 213 billion yuan reported [7]. - The total asset management scale for 34 firms with comparable data was 7.4 trillion yuan, reflecting a 2% year-on-year increase [7]. 5. Proprietary Trading - The net investment income for the first half of 2025 was 1,178 billion yuan, a 51% increase year-on-year, driven by favorable market conditions [7][34]. - The second quarter alone saw a net investment income of 671 billion yuan, marking a 53% year-on-year increase [7]. 6. Dividend Distribution - Mid-term cash dividends increased by 40% year-on-year, although the dividend payout ratio decreased by 3 percentage points [7][46]. - The average dividend yield for A-share listed securities firms was 1.30%, with Dongwu Securities having the highest yield at 3.1% [7]. 7. Profit Forecast - The report projects a 32% year-on-year increase in industry net profit for 2025, driven by active market trading and improved business conditions [8][19]. - The expected growth rates for various business segments include a 66% increase in brokerage income and an 18% increase in investment banking revenue [8].

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, but maintained strong cash flow and profitability metrics, indicating resilience despite market challenges [2][5]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.134 billion yuan, a year-on-year decrease of 24.15% - Net profit was 389 million yuan, down 29.46% compared to the previous year - Operating cash flow was 538 million yuan, exceeding net profit by 149 million yuan, reflecting high-quality cash flow [2]. Business Segment Performance - **Nephrology Sector**: Sales revenue from nephrology products reached 784.97 million yuan, accounting for 69.20% of total revenue. The KHA series products generated 79.98 million yuan in sales, up 27.34% year-on-year, while pHA series sales increased by 374.22% to 11.75 million yuan [3]. - **Hepatology Sector**: Revenue from hepatology products was 131.53 million yuan, representing 11.59% of total revenue [3]. - **Critical Care Sector**: Sales in this area totaled 142.31 million yuan, making up 12.54% of total revenue, with a notable 36.15% increase in sales from the CA series [3]. - **Blood Purification Equipment**: Revenue was 19.34 million yuan, accounting for 1.71% of total revenue [3]. - **International Business**: Overseas revenue reached 34.44 million yuan, representing 3.04% of total revenue, with products used in over 2,000 hospitals across 98 countries [3]. Research and Development - The company invested 97 million yuan in R&D, which is 8.59% of revenue, and obtained 15 new patents during the reporting period [4]. - Two products received CE certification under the latest EU MDR regulations, and a new product for medical waste disposal was registered [4]. Dividend and Social Responsibility - The company distributed a cash dividend of 620 million yuan (including tax), with a payout ratio exceeding 75% [4]. - It contributed 19.17 million yuan in cash and materials for public welfare projects during the reporting period [4]. Future Outlook - The company anticipates a decline in revenue due to price adjustments and high base effects from the previous year, but plans to deepen its focus on blood purification and expand both domestic and international markets [5]. - The company is exploring new business areas related to metabolic cardiovascular diseases and has initiated a clinical study on plasma adsorption in stroke patients [5]. - The company aims to maintain a stable and sustainable dividend policy, having distributed a total of 4.07 billion yuan since its IPO [5].

Summary of Key Points Core Viewpoint The company, Ningbo Jintian Copper Industry (Group) Co., Ltd., is undergoing a change in its fundraising investment projects to optimize resource allocation and enhance operational efficiency in response to market conditions and strategic planning. Group 1: Fundraising Overview - The company has been approved to issue convertible bonds totaling RMB 1.45 billion, with a net fundraising amount of RMB 1.45 billion after deducting issuance costs [1][2]. - The funds will be allocated to various projects, including a new project in Thailand for producing precision copper tubes [3][4]. Group 2: Changes in Investment Projects - The original project for producing 70,000 tons of precision copper alloy rods has been changed to two new projects: a 10,000-ton ultra-fine copper conductor project and an upgrade of the 450 copper alloy strip production line, involving RMB 26.69 million, which is 18.47% of the total net fundraising amount [5][6]. - The decision to change the project was influenced by a decline in demand in the real estate sector, which significantly affects the market for copper rods [7][8]. Group 3: New Project Details - The ultra-fine copper conductor project is expected to meet the growing demand in sectors such as new energy vehicles and 5G communications, with a projected annual revenue of RMB 82.56 million and a profit of RMB 5.65 million [9][12]. - The upgrade of the 450 copper alloy strip production line aims to produce high-end copper alloy strips, responding to the increasing demand from the electronics and automotive industries [11][15]. Group 4: Feasibility and Market Outlook - The new projects align with industry trends and national policies, indicating a strong market potential for high-precision copper products [14][16]. - The company has a solid technical foundation and experienced workforce, which will support the successful implementation of the new projects [17][18]. Group 5: Regulatory Compliance - The changes in investment projects have been approved by the company's board and supervisory committee and will be submitted for shareholder approval, ensuring compliance with relevant regulations [20][21].